New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMelanotan 1 vs Cartalax

Melanotan 1 vs Cartalax

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticSexual Health & Libido
Melanotan 1
Anti-Aging & Longevity
Cartalax
Summary
Melanotan 1 (Afamelanotide) is a synthetic analog of α-MSH that selectively stimulates melanogenesis (tanning) through MC1R activation. It provides UV-independent skin pigmentation and is FDA/EMA-approved under the name SCENESSE for erythropoietic protoporphyria (EPP) and vitiligo.
Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
Half-Life
~40–60 minutes (free peptide); implant formulation (SCENESSE) releases over months
Short (minutes); gene-regulatory effects are sustained
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
0.5–1 mg
10 mg per day
Frequency
Daily until desired color achieved, then maintenance
Daily for 10–30 days
Key Benefits
  • Induces skin pigmentation/tanning without UV exposure
  • Provides photoprotection in photosensitivity conditions (EPP)
  • FDA-approved for erythropoietic protoporphyria (SCENESSE)
  • Approved in EU for EPP treatment
  • Anti-inflammatory via MC1R
  • Mild libido enhancement
  • Potential skin cancer prevention through melanin protection
  • Supports cartilage matrix synthesis and maintenance
  • May slow progression of osteoarthritic cartilage degradation
  • Reduces chondrocyte apoptosis
  • Promotes joint longevity in aging and high-impact sports
  • Anti-aging effects on connective tissue
  • Complementary to BPC-157 and TB-500 in joint recovery protocols
  • Well tolerated in available human and animal research
Side Effects
  • Nausea (especially at higher doses)
  • Facial flushing
  • Fatigue
  • Injection site reactions
  • +3 more
  • Generally well tolerated
  • Mild injection site reactions
  • No significant adverse events reported at standard doses
Stacks With